Keyphrases
Adverse Events of Special Interest
6%
Area under the Concentration-time Curve
6%
Brensocatib
100%
Bronchiectasis
12%
Cathepsin G
6%
Chronic Inflammatory Diseases
6%
Clinical Outcomes
6%
Clinically Significant
6%
Covariate Effect
6%
Dipeptidyl Peptidase 1
100%
Distribution Function
6%
Dose Adjustment
6%
Dose Selection
6%
Efficacy Analysis
6%
Efficacy Index
6%
Elastase Activity
12%
Exposure Area
6%
First-in-class
6%
Further Development
6%
Healthy Adults
6%
Hyperkeratosis
6%
Intrapulmonary Pharmacokinetics
6%
Meaningful Connections
6%
Moderating Effect
6%
Neutrophil Elastase
56%
Non-cystic Fibrosis Bronchiectasis
100%
Once-daily
18%
Oral Clearance
6%
Periodontal Disease
6%
Periodontal Infection
6%
Pharmacodynamic Evaluation
100%
Pharmacodynamics
6%
Pharmacokinetic Analysis
6%
Pharmacokinetic Data
12%
Pharmacokinetics
25%
Pharmacokinetics-pharmacodynamics (PK-PD)
100%
Phase I Study
6%
Phase II Study
18%
Phase III Clinical Trial
6%
Population Pharmacokinetic Model
18%
Population Pharmacokinetics
12%
Potential Relationships
6%
Proteinase 3
6%
Pulmonary Exacerbation
25%
Pulmonary Infection
6%
Renal Function
12%
Renal Impairment
6%
Safety Assessment
6%
Safety Measures
6%
Selective Classes
6%
Sputum Neutrophils
31%
Steady State
6%
Volume of Distribution
6%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
7%
Bronchiectasis
100%
Cathepsin G
7%
Clinical Study
7%
Clinical Trial
7%
Cystic Fibrosis
100%
Dipeptidyl Peptidase
100%
Hyperkeratosis
7%
Inflammatory Disease
7%
Leukocyte Elastase
50%
Lung Infection
7%
Mild Renal Impairment
7%
Moderate Renal Impairment
7%
Myeloblastin
7%
Normal Human
7%
Periodontal Disease
14%
Pharmacodynamics
100%
Pharmacokinetics
100%
Serine Proteinase
14%
Volume of Distribution
7%